Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
Australia
Clinical Study Center, Melbourne Georgia
Clinical Study Center, Tbilisi United Kingdom
Clinical Study Center, London